维拉佐酮的药理和临床评价  

Pharmacology and clinical evaluation of vilazodone

作　　者：朱翊[1] 封宇飞[1] 

机构地区：[1]卫生部北京医院药学部,北京100730

出　　处：《中国新药与临床杂志》2012年第9期516-519,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：重性抑郁障碍是一种严重的精神障碍,且容易复发。尽管多种药物均可治疗,但仍有许多患者无法获得满意的疗效。维拉佐酮为选择性5-HT再摄取抑制剂和5-HT_(1A)受体部分激动剂,用于治疗重性抑郁障碍。本文就其作用机制、药效学、药动学和临床评价等进行综述。Major depressive disorder （MDD） is a serious mental disorder and easy to relapse. Despite many kinds of antidepressant drugs are available, most patients fail to achieve an adequate treatment response. Vilazodone, a novel dual-acting serotonergic antidepressant combined selective 5-HT reuptake inhibition with partial agonism of the 5-HT1A receptor, is indicated for the treatment of MDD. The mechanism, pharmacodynamics, pharmacokinetics and clinical evaluation of vilazodone were reviewed in this paper.

关 键 词：维拉佐酮 抑郁症 选择性5-HT再摄取抑制剂 血清素激动药 药理作用 药物评价 

分 类 号：R749[医药卫生—神经病学与精神病学]